Depression Treatment Adjunct — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for depression treatment adjunct. 270 active patents protecting 2 drugs from 2+ originators. First major cliff: 2031. Daily refresh.

2
Approved drugs
270
Active US patents
63/100
Avg vulnerability
$3.3B
Annual revenue covered

Originators in Depression Treatment Adjunct

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Generic (originally Otsuka/BMS) 214 patents Eli Lilly 56 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating depression treatment adjunct. Each bar = one year. Y-axis scaled to peak year (54 patents).

20
26
21
27
6
28
54
29
48
30
48
31
10
32
37
33
8
34
3
40

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Abilify
aripiprazole
 Generic (originally Otsuka/BMS) 214 61 $3.0B 2026-07-28
Zyprexa
olanzapine
 Eli Lilly 56 64 $300M 2031-08-23

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
8759350 Abilify method of use 85 2027-03-02
8759350 Abilify method of use 85 2027-03-02
8759350 Abilify method of use 85 2027-03-02
8759350 Abilify method of use 85 2027-03-02
8759350 Abilify method of use 85 2027-03-02
8759350 Abilify method of use 85 2027-03-02
8759350 Abilify method of use 85 2027-03-02
8759350 Abilify method of use 85 2027-03-02
8759350 Abilify method of use 85 2027-03-02
12194035 Zyprexa method of use 81 2031-08-23

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
9119848 Zyprexa composition of matter 10 2031-08-30
9119848 Zyprexa composition of matter 10 2031-08-30
9119848 Zyprexa composition of matter 10 2031-08-30
9119848 Zyprexa composition of matter 10 2031-08-30
10517507 Abilify formulation 42 2032-06-13
10517507 Abilify formulation 42 2032-06-13
10517507 Abilify formulation 42 2032-06-13
10517507 Abilify formulation 42 2032-06-13
10517507 Abilify formulation 42 2032-06-13
10517507 Abilify formulation 42 2032-06-13

Related